18 results about "Metabolism pathway" patented technology

The invention discloses synthesis and pharmacodynamic toxicological research of an acetaminophen derivative, the acetaminophen derivative has a structure as shown in the following formula (I) or a pharmaceutically acceptable salt thereof, in the formula (I), R1 is selected from-OH, F, Cl or Br; r2 is selected from S or O; when R2 is O, R1 is not-OH; and preferably, R2 is S. The invention designs and synthesizes a series of APAP-based novel derivatives from the perspective of changing the metabolic pathway of the drug by carrying out reasonable drug modification on APAP, and reduces the toxic and side effects of the original drug while exerting the biological activity similar to or higher than that of the original drug.

This invention provides the application of gonococcal ferritin in the preparation of anti-gonococcal products, relating to the field of antibody technology. The application of gonococcal ferritin subunits in the preparation of antibodies against gonococcal ferritin inhibits gonococcal infection by intervening in the iron metabolism pathway of gonococci, without inducing classic drug resistance mutations. This overcomes the limitations of existing technologies that rely on antibiotics, achieving broad-spectrum inhibition of drug resistance lineages. It solves the technical problem in existing technologies where multidrug / pan-drug resistance of gonococci leads to complete failure of antibiotic treatment, and the lack of therapeutic targets targeting its core survival mechanisms.

The invention discloses a high-yield cell-free protein synthesis system based on a cell crude extract and application of the high-yield cell-free protein synthesis system. The system comprises an escherichia coli extract, a DNA template, a buffer solution, an amino acid mixture, a nucleoside triphosphate mixture, an ATP regeneration system and antibiotics, the antibiotics are selected from compounds having inhibitory activity on metabolic processes except ribosome functions in prokaryotic microorganisms, including but not limited to one or more combinations of interfering DNA replication, DNA transcription, cell wall synthesis, energy metabolism, lipid synthesis or other non-translational related metabolic pathways. According to the method disclosed by the invention, the escherichia coli crude extract is used as a bacterial chassis, and non-essential metabolic pathways in a CFPS system are selectively inhibited by introducing different types of antibiotics, so that the yield of protein synthesis is increased.

The invention discloses a genetically engineered bacterium for biosynthesis of inositol and application of the genetically engineered bacterium for biosynthesis of inositol, and the genetically engineered bacterium for biosynthesis of inositol is obtained by co-expressing a sweet orange inositol-3-phosphate synthase gene Csino3 and an escherichia coli inositol-1-monophosphate gene suhB in recombinant escherichia coli and then knocking out a glucose phosphate isomerase gene pgi. According to the technical scheme, the yield of inositol produced by the strain reaches 2.04 g / L and is increased by about 6.6 times compared with that before optimization, the inositol yield is greatly increased, the metabolic flux of glycolysis to glucose-6-phosphoric acid is effectively blocked, carbon metabolic flux is forced to be redirected to a pentose phosphate pathway, glucose-6-phosphoric acid is enriched, and a raw material is provided for inositol production. By blocking downstream branches of a glycometabolism pathway, enrichment of glucose-6-phosphate in cells is realized, so that sufficient precursor substances are provided for synthesis of inositol, and finally the yield of inositol is increased. The technical scheme is expected to be applied to construction of microbial cell factories, so that large-scale and low-cost production of inositol is realized, and theoretical support is provided for development of related industries.

The invention belongs to the technical field of plant molecular biology, and relates to application of a gene CmZFP for regulating and controlling sucrose accumulation of muskmelon fruits. The CmZFP gene provided by the invention encodes a melon zinc finger protein transcription factor, can significantly improve the accumulation of sucrose in melon fruits by promoting the expression of a key gene CmNAG2 in a glycometabolism pathway, and plays an important role in the glycometabolism pathway. The invention provides a new gene resource for genetic improvement of the sugar character of the muskmelon, and can be used for cultivating a new variety of the high-sugar muskmelon and improving the fruit quality and the economic benefit.

The invention belongs to the technical field of biological agents and feed, and discloses a biological agent and application thereof in low-protein feed. The core component of the biological agent is rumen bypass glycine (RPGly), and the biological agent is micro-capsule type particles and is composed of an inner layer coating composed of a glycine capsule core, hydrophobic beewax and hydrogenated castor oil, and an outer layer coating containing chitosan and nano silicon dioxide. The preparation has excellent rumen bypass rate and small intestine release rate, and can be cooperatively used with rumen bypass methionine. When being applied to low-protein feed for ruminants, the low-protein feed additive can regulate and control metabolic pathways such as glyceryl phospholipids and glutathione, so that nitrogen emission is remarkably reduced, the growth performance of animals is maintained, the eye muscle area is remarkably increased, the tenderness and flavor of meat are improved, and quality and efficiency improvement in a low-protein breeding mode is realized.

The present disclosure concerns recombinant yeast host cells having a first genetic modification for downregulating a first metabolic pathway that converts NADP+ to NADPH, as well as a second genetic modification for upregulating a second metabolic pathway that converts NADP+ to NADPH. The second genetic modification allows the expression of a glyceraldehyde-3-phosphate dehydrogenase lacking phosphorylating activity, which can, in some embodiments, be from enzyme commission 1.2.1.9 or 1.2.1.90. The second pathway is distinct from the first metabolic pathway. The present disclosure also concerns a process for making and improving the yield of a fermented product, such as ethanol, using the recombinant yeast host cell.

This invention relates to the field of biotechnology, and more particularly to a method for alleviating high-starch-induced liver damage and glucose metabolism disorders in sea bass. The feed formulation proposed in this invention comprises 20%-22% cassava starch and 2%-6% mulberry leaf polysaccharides, among other components. This application discloses that mulberry leaf polysaccharides and the high starch content in the feed form a highly efficient synergistic effect, significantly improving the growth performance of sea bass, effectively reducing the accumulation of glycogen and fat in the liver, and significantly improving liver health. Simultaneously, it optimizes the blood glucose regulation capacity of sea bass, alleviates insulin resistance caused by a high-starch diet, and enhances insulin sensitivity. Furthermore, by activating mechanisms such as the PI3K / Akt signaling pathway, it optimizes the glucose metabolism pathway and promotes efficient energy utilization. The feed formulation of this invention is economical and efficient, providing solid scientific support for the healthy aquaculture of sea bass and powerfully promoting the sustainable development of aquaculture.

The invention provides an application of metformin in preparation of a medicine for preventing or treating immune checkpoint inhibitor related colitis. It is found through experiments that when the immune checkpoint inhibitor causes colitis, change of metabolic level represented by glycolysis caused by change of a PI3K / AKT / mTOR pathway in the colon is obviously accompanied, then Treg / Th17 steady state in the colon is affected, and a high inflammatory state is shown in the colon. According to the present invention, the influence on glycolysis and other metabolic pathways is achieved through the targeted interference of the metformin on the PI3K / AKT / mTOR pathway, the colitis caused by the immune checkpoint inhibitor can be significantly improved, the anti-tumor drug effect of the immune checkpoint inhibitor is not affected, and the method is generally superior to the original clinical methylprednisolone intervention scheme.

The application relates to a genetically engineered body, and particularly discloses a perilla frutescens PfCHLH gene and a virus-induced gene silencing system, a construction method and application of the gene silencing system. PfCHLH The nucleotide sequence of the gene is shown as SEQ ID NO. 1, and the amino acid sequence of the encoded protein is shown as SEQ ID NO. 2. PfCHLH The gene silencing fragment is cloned into a virus carrier pTRV2 to obtain a pTRV2- PfCHLH silencing carrier, and the pTRV2 carrier and the pTRV1 carrier are respectively transformed into agrobacterium GV3101 to prepare infection bacterial liquid; the infection bacterial liquid is mixed according to a volume ratio of 1:1 and then injected into perilla frutescens cotyledons to induce gene silencing. PfCHLH qRT-PCR verification shows that the expression amount is significantly down-regulated and a stable yellowing phenotype is generated; preferably, the OD 600 of the infection bacterial liquid is 0.6, the silencing phenotype is more significant, and the consistency is better. The perilla frutescens VIGS system established in the application is simple in operation, short in cycle, and high in efficiency, and can be used for rapid identification of perilla frutescens gene functions and verification and application of key genes in related metabolic pathways.

The invention develops a Klotho protein delivery system based on recombinant lactic acid bacteria. The Klotho protein delivery system is characterized in that optimized Klotho genes are integrated into a food-grade carrier pNZ8149 through genetic engineering, and the food-grade carrier pNZ8149 is introduced into lactococcus lactis NZ3900 to construct a recombinant strain for expressing Klotho protein; and the functional Klotho protein can be efficiently secreted through Nisin induction. The preparation is orally taken in the form of viable bacteria to feed chicks, targeted release of Klotho protein is realized through intestinal colonization, and experiments prove that the preparation can synergistically activate growth and metabolism pathways (the weight of 21-day-old chicks is increased, and the feed conversion ratio is reduced) and improve intestinal health. The technology breaks through the limitation that traditional probiotics are lack of functional protein delivery capacity, an antibiotic / hormone growth promoter is replaced by a green scheme without resistance and zero residue, and a new safe and efficient growth regulation strategy is provided for livestock and poultry breeding.

The application provides a traditional Chinese medicine composition for treating diabetic nephropathy and an application, and relates to the technical field of traditional Chinese medicine pharmacy.The traditional Chinese medicine composition is composed of Nanhaiteng, Tianhuafen, Xia' erxiancao, Heilu, Luohua'zi, Gegen, Corn silk, Gansui, Zhushenfen, Huangqi and Danshen.The traditional Chinese medicine composition can significantly improve blood glucose, blood lipid indexes and kidney function indexes of diabetic nephropathy rats, regulate the internal environment of the body, improve insulin resistance, and protect the kidney function of the rats.In addition, the traditional Chinese medicine composition can reduce the FPG, 2hPBG, HbA1c, Scr, BUN and UAER levels of diabetic nephropathy patients, regulate the sugar metabolism pathway of the body, reduce the blood glucose level of the patients, improve the kidney function of the patients, reduce the related TCM syndrome score of the patients, relieve clinical symptoms, and provide a scheme with remarkable effect and high safety for the treatment of diabetic nephropathy.

The application discloses a Corynebacterium glutamicum with high N-acetylglucosamine yield and application, and belongs to the technical field of genetic engineering.The GlcNAc synthesis pathway is constructed in the Corynebacterium glutamicum, the related genes of the decomposition and metabolism pathways of the chassis cell and the byproduct metabolism pathway are inhibited, and the endogenous key enzyme glmS is subjected to D80W / I381N mutation, so that the constructed engineering strain can synthesize and accumulate N-acetylglucosamine outside cells in a large amount, the yield reaches 152 g / L in a 50 L fermenter, and the production intensity reaches 2.11 g / L ‑1 .h ‑1 The genetically engineered bacteria are safe and non-toxic, the fermentation method has high yield, simple cost, strong practicability and wide application prospect.

The application discloses a metabolism regulation mechanism analysis method for treating WD liver fibrosis by using Gandouling, and belongs to the technical field of medicines, and comprises the following steps: blood component and network pharmacology research; obtaining metabolism markers significantly adjusted by Gandouling based on serum metabolomics, and performing enrichment analysis on the metabolism markers significantly adjusted by Gandouling to obtain significant metabolism pathways; constructing a complex metabolism network of "small molecule metabolite-reaction-enzyme-target"; screening a pharmacodynamic material basis of Gandouling by using molecular docking technology; and visualizing a multi-dimensional network of "pharmacodynamic material basis of Gandouling-core action target-core metabolism marker-core metabolism pathway-WD liver fibrosis". The application obtains 25 pharmacodynamic material bases, 11 core action targets, 12 core metabolism markers and 9 core metabolism pathways.

The invention relates to a drug recommendation method based on a diffuse large B-cell lymphoma medical image and a computer model. The drug recommendation method is based on a typing method, typing takes a tumor maximum mass diameter (MTD) as a core, and patients are divided into a non-large mass type (MTDlt, 5cm), a medium large mass type (5cm < = MTDlt, 10cm) and a huge mass type (MTD > = 10cm) in combination with CD58, STAT6 and EBF1 gene mutation probabilities, MYC, BCR, PI3K and other carcinogenic pathways and cell proliferation and sugar metabolism pathway activation degrees. The computer model adopts a deep learning architecture, can evaluate prognosis and guide treatment by inputting imaging photos, automatically analyzing the characteristics of a packet block, determining typing and outputting individualized drug recommendation in combination with the characteristics of molecules and pathways, is suitable for the medical field of hospitals, and particularly provides a convenient tool for mechanisms lacking gene sequencing conditions.

The invention provides a functional gene capable of maintaining immune memory of stichopus japonicus. The amino acid sequence of a protein coded by the functional gene is SEQ ID NO: 2. The gene is activated when the stichopus japonicus is infected by low-concentration vibrio splendidus, and can keep a relatively stable expression level; by regulating and controlling the metabolic pathway of the immune memory cells, the immune memory cells are converted to the glycolysis direction, so that rapid and sufficient energy support is provided for immune response; meanwhile, the gene can also effectively enhance the phagocytic function of coelomic cells of the stichopus japonicus, and obviously improve the ability of the stichopus japonicus to remove pathogenic microorganisms. Discovery and application of the gene provide a new molecular basis for research on a maintenance mechanism of immune memory of the stichopus japonicus, and lay a theoretical and practical foundation for prevention and control of stichopus japonicus diseases and development of a novel immune regulation method.

The present application relates to the technical field of renal cell carcinoma, and particularly relates to a method for predicting the lipid metabolism regulation mechanism of renal cell carcinoma, which is characterized by the following steps: determining the expression difference of EMT, cell proliferation and apoptosis proteins in groups through molecular detection, and determining the difference of fat pathway genes, oil accumulation degree and fat factor expression level in groups, and determining the correlation between lipid metabolism and GAD2, the present project first proposes the miR-metabolic enzyme-lipid pool regulation axis, which is different from the traditional mode of miR directly targeting proliferation genes. Previous studies have focused on the regulation of miRNA on directly related genes such as tumor cell proliferation and apoptosis, and the present project starts from the fat metabolism pathway and deeply explores the regulation of miR-362-5p targeting GAD2 gene on the progression of renal cell carcinoma (RCC). This innovation provides a new perspective and theoretical framework for RCC research, and is expected to open up a new treatment idea, and a systematic research system from clinical samples, cell experiments, molecular detection to animal experiments is constructed.

A computer-implemented method for genetic data processing. The processing method including obtaining a dataset comprising microbial gene expression data for a plurality of patients. The method comprises clustering the plurality of patients into a set of clusters based on the microbial gene expression data. The method comprises determining genes of which expression explains the clustering by selecting genes included in a set of metabolic pathways and / or by identifying genes exhibiting significantly different expressions across the clusters. The method forms an improved solution for patient stratification based on metagenomic data.